Mead Andrew, Richez Pascal, Azzariti Stefano, Pelligand Ludovic
Comparative Biomedical Sciences, The Royal Veterinary College, London, United Kingdom.
Transpharm, Saint-Genies des Mourgues, France.
Front Vet Sci. 2021 Jun 24;8:698135. doi: 10.3389/fvets.2021.698135. eCollection 2021.
Colistin, a last-line antibiotic of major importance in veterinary medicine and of critical importance in human medicine, is authorized to treat gastrointestinal (enteric) infections caused by non-invasive in multiple veterinary species including poultry. Its use in veterinary medicine has been implicated in the widespread prevalence of mobilized colistin resistance. The objectives of this study were to determine the intestinal content reached in broiler chickens during 72-h treatment with colistin, to evaluate the associated impact on intestinal density, and to select less susceptible populations. In this study, 94 broiler chickens were administered a dose of 75,000 IU/kg/day via drinking water. Intestinal samples were collected pre-, during-, and post-dosing. Luminal intestinal content was assessed for colistin content by ultra-high-performance liquid chromatography-tandem mass spectrometry (UHPLC-MS/MS), and were isolated and enumerated on UriSelect agar™. Minimum inhibitory concentration (MIC, for eight isolates per intestine per animal) was determined, and when higher than the epidemiological cutoff (ECOFF 2 mg/l), isolates were screened for mobilized colistin resistance (mcr)-1 to 5. Colistin content increased during treatment to a maximum of 5.09 mg/kg. During this time, the total population of showed an almost 1,000-fold reduction. An apparent increase in the relative abundance of with an MIC ≥ ECOFF, either mcr-negative (6.25-10.94%) or mcr-1-positive (4.16-31.25%) was observed, although this susceptibility shift was not maintained post-treatment. Indeed, following cessation of dosing, colistin was eliminated from the intestine, and content was below the limit of quantification (LOQ, 1.1 mg/kg) within 4 h, and the median MIC of isolates returned below baseline thereafter. Few isolates with a lower susceptibility (mcr-1-positive or negative) were however observed at the end of the study period, indicating maintained sub-populations in the chicken gut. The results of this study show a limited impact on long-term maintenance of less susceptible populations as a direct result of colistin treatment in individual birds.
黏菌素是兽医学中极为重要的最后一线抗生素,在人类医学中也至关重要,被批准用于治疗包括家禽在内的多种兽类由非侵袭性细菌引起的胃肠道(肠道)感染。其在兽医学中的使用与可转移黏菌素耐药性的广泛流行有关。本研究的目的是确定肉鸡在接受黏菌素72小时治疗期间肠道内达到的药物含量,评估其对肠道细菌密度的相关影响,并筛选出较不易感的细菌群体。在本研究中,94只肉鸡通过饮水给予75,000国际单位/千克/天的剂量。在给药前、给药期间和给药后采集肠道样本。通过超高效液相色谱-串联质谱法(UHPLC-MS/MS)评估肠腔内容物中的黏菌素含量,并在UriSelect琼脂™上分离和计数细菌。测定最低抑菌浓度(MIC,每只动物每个肠道的8个分离株),当高于流行病学临界值(ECOFF 2毫克/升)时,对分离株进行可转移黏菌素耐药性(mcr)-1至5的筛查。治疗期间黏菌素含量增加,最高达到5.09毫克/千克。在此期间,细菌总数减少了近1000倍。观察到MIC≥ECOFF的细菌相对丰度明显增加,无论是mcr阴性(6.25 - 10.94%)还是mcr-1阳性(4.16 - 31.25%),尽管这种敏感性变化在治疗后并未持续。事实上,停药后,黏菌素从肠道中消除,4小时内含量低于定量限(LOQ,1.1毫克/千克),此后细菌分离株的MIC中位数恢复到基线以下。然而,在研究期结束时观察到少数敏感性较低的分离株(mcr-1阳性或阴性),表明鸡肠道中存在持续的亚群。本研究结果表明,黏菌素治疗个体鸡只对较不易感细菌群体的长期维持影响有限。